Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) (ERMES study)

被引：0
|
作者：
Normanno, Nicola
Orlandi, Armando
Maiello, Evaristo
Rachiglio, Anna Maria
Maglietta, Giuseppe
Damato, Angela
Calegari, Maria Alessandra
Antonuzzo, Lorenzo
Bordonaro, Roberto
Zampino, Maria Giulia
Tamberi, Stefano
Lonardi, Sara
Tonini, Giuseppe
Rosati, Gerardo
Latiano, Tiziana Pia
Tamburini, Emiliano
Maiello, Monica Rosaria
Carotenuto, Marianeve
Barone, Carlo
Pinto, Carmine
机构：
[1] Ist Nazl Tumori IRCCS Fdn Pascale, Cell Biol & Biotherapy Unit, Naples, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, UOC Oncol Med, Rome, Italy
[3] Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy
[4] Ist Nazl Tumori IRCCS Fdn G Pascale, Cell Biol & Biotherapy Unit, Naples, Italy
[5] Univ Hosp Parma, Clin & Epidemiol Res Unit, Parma, Italy
[6] AUSL IRCCS Reggio Emilia, Comprehens Canc Center, Med Oncol Unit, Reggio Emilia, Italy
[7] Fdn Policlin Univ Agostino Gemelli IRCCS, Ctr Comprehens Canc, Oncol Med, Rome, Italy
[8] Careggi Univ Hosp, Dept Expt & Clin Med, Clin Oncol Unit, Florence, Italy
[9] Azienda Osped ARNAS Garibaldi, Med Oncol, Catania, CT, Italy
[10] Ist Europeo Oncol IRCCS, Med Oncol Deparment, Milan, Italy
[11] Santa Maria Croci Hosp, Oncol Unit, Ravenna, Italy
[12] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Padua, Italy
[13] Univ Campus Biomed, Dept Med Oncol, Rome, Italy
[14] Azienda Osped S Carlo, Potenza, Italy
[15] Fdn IRCCS Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, Italy
[16] Tricase City Hosp, Dept Oncol, Tricase, Italy
[17] Policlin Univ Agostino Gemelli, UOC Oncol Med, Rome, Italy
[18] AUSL IRCCS, Med Oncol Unit, Ctr Comprehens Canc, Reggio Emilia, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3544
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Hitoshi Soda
    Hiromichi Maeda
    Junichi Hasegawa
    Takao Takahashi
    Shoichi Hazama
    Mutsumi Fukunaga
    Emiko Kono
    Masahito Kotaka
    Junichi Sakamoto
    Naoki Nagata
    Koji Oba
    Hideyuki Mishima
    BMC Cancer, 15
  • [42] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Soda, Hitoshi
    Maeda, Hiromichi
    Hasegawa, Junichi
    Takahashi, Takao
    Hazama, Shoichi
    Fukunaga, Mutsumi
    Kono, Emiko
    Kotaka, Masahito
    Sakamoto, Junichi
    Nagata, Naoki
    Oba, Koji
    Mishima, Hideyuki
    BMC CANCER, 2015, 15
  • [43] Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
    Samalin, Emmanuelle
    Mazard, Thibault
    Assenat, Eric
    Rouyer, Magali
    de la Fouchardiere, Christelle
    Guimbaud, Rosine
    Smith, Denis
    Portales, Fabienne
    Ychou, Marc
    Adenis, Antoine
    Fiess, Catherine
    Lopez-Crapez, Evelyne
    Thezenas, Simon
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1375 - 1381
  • [44] First-line FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC): the open-label, randomized phase 3 TAILOR trial
    Qin, S.
    Xu, J.
    Wang, L.
    Cheng, Y.
    Liu, T.
    Chen, J.
    Eggleton, S. P.
    Liu, J.
    Li, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 141 - 141
  • [45] Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
    Stintzing, Sebastian
    Jung, Andreas
    Rossius, Lisa
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Al-Batran, Salah-Eddin
    Vehling-Kaiser, Ursula
    Heintges, Tobias
    Moehler, Markus
    Scheithauer, Werner
    Kirchner, Thomas
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [46] A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)
    Cascinu, S.
    Lonardi, S.
    Rosati, G.
    Nasti, G.
    Zaniboni, A.
    Romiti, A.
    Aglietta, M.
    Bilancia, D.
    Iaffaioli, V.
    Zagonel, V.
    Giordano, M.
    Corsi, D.
    Ferrau, F.
    Labianca, R.
    Berardi, R.
    Rulli, E.
    Floriani, I.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S329 - S329
  • [47] Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Juergen
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Hielscher, Joerg
    Scholz, Michael
    Mueller, Sebastian
    Schaefer, Britta
    Modest, Dominik Paul
    Jung, Andreas
    Stintzing, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [48] Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).
    Cheng, Ann-Lii
    Cornelio, Gerardo H.
    Shen, Lin
    Price, Timothy Jay
    Yang, Tsai-Shen
    Chung, Ik-Joo
    Dai, Guanghai
    Lin, Jen-Kou
    Sharma, Atul
    Yeh, Kun-Huei
    Ma, Brigette
    Zaatar, Adel
    Guan, Zhongzhen
    Masood, Nehal
    Srimuninnimit, Vichien
    Yau, Thomas Cheung
    Sarholz, Barbara
    Lim, Robert S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.
    Antoniotti, Carlotta
    Cremolini, Chiara
    Loupakis, Fotios
    Bergamo, Francesca
    Grande, Roberta
    Tonini, Giuseppe
    Garattini, Silvio Ken
    Masi, Gianluca
    Battaglin, Francesca
    Lucchesi, Sara
    Salvatore, Lisa
    Corsi, Domenico C.
    Di Fabio, Francesca
    Banzi, Maria
    Sensi, Elisa
    Tomcikova, Daniela
    Fontanini, Gabriell
    Zagonel, Vittorina
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Cost-effectiveness of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study
    Stintzing, Sebastian
    van Oostrum, Ilse
    Pescott, Chris
    Steinbach-Buechert, Alma Katharina
    Heeg, Bart
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345